Although bats are increasingly being recognized as natural reservoir hosts of emerging zoonotic viruses, little is known about how they control and clear virus infection in the absence of clinical disease. Here, we test >50 convalescent sera from Egyptian rousette bats (ERBs) experimentally primed or prime-boosted with Marburg virus, Ebola virus, or Sosuga virus for the presence of virus-specific neutralizing antibodies, using infectious reporter viruses. After serum neutralization testing, we conclude that antibody-mediated virus neutralization does not contribute significantly to the control and clearance of Marburg virus, Ebola virus, or Sosuga virus infection in ERBs.
The order Mononegavirales is the taxonomic home of numerous zoonotic viruses, including filoviruses and paramyxoviruses. The Egyptian rousette bat (ERB; Rousettus aegyptiacus) is a natural reservoir host of Marburg virus (MARV; family Filoviridae, genus Marburgvirus) [1] , a putative natural reservoir host of Sosuga virus (SOSV; family Paramyxoviridae, unclassified rubulavirus-like virus) [2] , and a dead-end host of Ebola virus (EBOV; family Filoviridae, genus Ebolavirus) [3, 4] . Although ERBs infected with any one of these viruses exhibit no signs of clinical illness, humans often develop severe disease after infection. Shortly following experimental inoculation of ERBs with MARV [5] [6] [7] or SOSV (authors' unpublished data), the bats develop viremia and exhibit high viral loads in multiple tissue specimens, oral swab specimens, rectal swab specimens, and urine specimens. In contrast, ERBs experimentally infected with EBOV exhibit low viral loads in a limited number of tissue specimens and fail to develop viremia or detectable viral shedding [3, 4] . Despite these differences in viral infection dynamics, bats infected with any one of these viruses develop virus-specific immunoglobulin G (IgG) antibody levels that begin to rise around 10 days after infection and peak between 14 and 28 days after infection [3, [5] [6] [7] . For MARV [5] [6] [7] and SOSV, the end of viral shedding typically coincides with peak virus-specific IgG antibody levels.
The long-term dynamics of the virus-specific IgG antibody response and the outcomes of reexposure to the virus have been investigated in ERBs infected with MARV only. Schuh et al [7] demonstrated that, once bats attain peak virus-specific IgG antibody levels following experimental or "natural" infection with MARV, the antibody levels rapidly decline and fall below the threshold of seropositivity by 3 months after infection. After both groups of these seronegative bats were experimentally challenged with homologous virus 17-24 months later, they developed robust secondary immune responses by 7 days after infection, in the absence of detectable virus replication or shedding, suggesting that primary infection induces long-term protective immunity against reinfection with a homologous virus [8] . Storm et al [9] showed MARV-specific IgG antibodies were still detectable in the majority of experimentally infected ERBs 4 months after infection and in naturally infected bats 11 months after initial capture. Following experimental challenge of the latter group of bats with a heterologous strain of MARV, some of the bats had detectable viral RNA in the blood, and 1 bat had a MARV-positive nasal swab specimen. However, the bats developed secondary MARV-specific immune responses by 5 days after infection, and virus was not detected in any tissues that might lead to shedding and transmission, such as the salivary glands, intestine, reproductive tract, and bladder. This suggests that, although MARV IgG antibodies were not completely protective against reinfection with a heterologous MARV strain, they may have prevented widespread viral dissemination to tissues and shedding.
While ERBs are able to effectively control and clear MARV, SOSV, or EBOV infection, it is unclear whether these events are mediated by the neutralizing ability of virus-specific IgG antibodies. Paweska et al [5] , showed that 33% of ERBs inoculated with MARV possessed low levels of neutralizing antibodies (titers of 1:4 to 1:8) 21 days after infection; however; it is possible that viral neutralization activity increases later during convalescence or after a secondary MARV exposure. Although Storm et al [9] demonstrated that pooled sera from wild-caught, MARV-seropositive ERBs was able to minimally reduce the titer of a locally circulating strain of MARV, from 7.2 to 6.2 log 10 50% tissue culture infective doses/mL, pooling of the sera precluded examination of individual heterogeneities in virus neutralization ability and the ability to determine whether virus neutralization is a prominent feature of virus clearance at the population level. In this study, we tested >50 convalescent sera collected from ERBs that had been experimentally primed or prime-boosted with MARV, EBOV, or SOSV for the presence of virus-specific neutralizing antibodies, using homologous infectious reporter viruses.
METHODS

Biosafety
All neutralization assays were performed in a biosafety level 4 laboratory at the Centers for Disease Control and Prevention, and all filovirus work was performed in compliance with Select Agent Regulations (Animal and Plant Health Inspection Service and Centers for Disease Control 2014).
Informed Consent
Informed consent and approval by the institutional review board were obtained prior to using the SOSV convalescent human sera.
Sera
We prescreened convalescent and naive plasma/sera specimens, as well as the MR201 MARV monoclonal antibody [10] , to identify appropriate positive and negative controls for subsequent virus-specific neutralizing assays (Table 1) . Convalescent ERB plasma/sera specimens (the majority of which had high IgG antibody levels) from previous experimental virus infection studies were used as test samples (Table 1) . Briefly, MARV convalescent bat plasma/sera specimens were generated in 3 ways. Bats in group 1 were experimentally primed with MARV and experimentally boosted with homologous virus 22 months later, and convalescent plasma specimens were collected 3 weeks later [7, 8] . ERBs in group 2 were "naturally" infected with MARV in a laboratory environment through contact with infectious bats and experimentally boosted with homologous virus 15 months later, and convalescent plasma specimens were collected 3 weeks later [7, 8] . Bats in group 3 were experimentally primed with MARV and experimentally boosted with homologous virus 2 months later, and convalescent sera were collected 3 weeks later. EBOV convalescent bat sera were generated by experimentally priming ERBs with EBOV, boosting them with homologous virus 2 months later, and collecting antisera 3 weeks later. SOSV convalescent bat sera were generated by experimentally inoculating ERBs with SOSV and collecting antisera 3 weeks later. The group 3 MARV convalescent bat sera and the EBOV convalescent bat sera were generated as part of an unpublished study evaluating the level of serological cross-reactivity between filovirus-specific bat antisera and heterologous filovirus antigen, while the SOSV convalescent sera originated from an unpublished experimental infection study designed to assess if the ERB is a competent natural reservoir host for SOSV.
Viruses
The following replication-competent, infectious recombinant (r) viruses that express the fluorescent ZsGreen1 (ZsG) protein in infected cells were used in the experiments: rMARV-ZsG (GenBank accession number MK271062; Huh7+2), rEBOVZsG (GenBank accession number KR781609; Huh7+2), and rSOSV-ZsG (GenBank accession number MG880225; BHK+3, Vero E6+3).
100% Focus Reduction Neutralization Test (FRNT 100 )
Test and control sera were heat inactivated at 56°C for 30 minutes prior to testing. All sera were screened for the presence of virus neutralizing antibodies, using a FRNT 100 . Two-fold serial dilutions of the sera, ranging from 1:8 to ≥1:128 (from 325 to 20 μg/mL for MR201), were prepared in dilution medium (FlouroBrite Dulbecco's modified Eagle's medium [DMEM] containing penicillin/streptomycin and GlutaMAX). Each serum dilution series was mixed with an equal volume of dilution medium (100 μL) containing 150 TCID 50 /20 μL of virus and then incubated on a plate rocker for 1 hour at 37°C. All serum dilution series included serum, virus, and reagent controls. Following incubation, 40 μL of each serum-virus mixture was inoculated in quadruplicate onto monolayers of 95% confluent Vero E6 cells in 96-well clear-bottomed black plates containing maintenance medium (FlouroBrite DMEM supplemented with 5% heat-inactivated fetal bovine serum [HI-FBS], penicillin/ streptomycin, and GlutaMAX). Plates were then incubated at 37°C in 5% CO 2 (duration, 2 days for SOSV, 3 days for EBOV, and 4 days for MARV). Following incubation, plates were viewed under a fluorescence microscope, and each well was scored for the presence, reduction, or absence of virus, as indicated by cells containing green foci. The FRNT 100 was defined as the reciprocal of the highest serum dilution for which the average virus infectivity was reduced by 100% when compared to the corresponding virus control wells.
FRNT 50
Test sera and relevant controls that exhibited FRNT 100 values ≥8 or a dilution effect were tested by FRNT 50 . One set of 2-fold serial dilutions of the serum samples, ranging from 1:8 to ≥1:2048 (from 325 to 1 μg/mL for MR201), was prepared in dilution medium, while the second set was prepared in dilution medium containing 5% guinea pig complement (GPC). Each serum dilution series was mixed with an equal volume of dilution medium (100 μL) containing 125-164 TCID 50 /20 μL of virus and then incubated on a plate rocker for 1 hour at 37°C. Following incubation, 40 μL of each serum-virus mixture and controls were inoculated in quadruplicate onto monolayers of 95% confluent Vero E6 cells in 96-well black-bottomed plates. After the plates were incubated on a plate rocker for 1 hour at 37°C, the virussera mixtures were removed, the cell monolayers were washed once with PBS, and 250 μL of carboxymethyl cellulose agar (1:1 mixture of 3% carboxymethyl cellulose sodium salt to 2X MEM supplemented with 8% HI-FBS, penicillin/streptomycin, and sodium pyruvate) was added to the wells. Plates were then incubated at 37°C in 5% CO 2 (duration, 2 days for SOSV and 4 days each for EBOV and MARV). The BioTek Cytation 3 Cell Imaging Multi-Mode Reader imaged and counted the number of green foci in each well. The FRNT 50 was defined as the reciprocal of the highest serum dilution for which the average virus infectivity was reduced by 50% when compared to the corresponding virus control wells.
RESULTS
The MARV FRNT 100 value of MR201 was >325 µg/mL (>32.5 µg); however, it exhibited a visual reduction in the number of viral foci at higher antibody concentrations (dilution effect) and was selected as the positive control for subsequent MARV neutralization assays. Two naive ERB plasma specimens (726415 and 725904) exhibited MARV FRNT 100 values <8 and were selected as negative controls for subsequent testing. All 30 MARV convalescent ERB plasma/sera specimens from groups 1-3 exhibited MARV FRNT 100 values <8; however, 1 plasma specimen from group 1 (685734) exhibited a dilution effect at lower plasma concentrations and was subjected to further testing. The MARV FRNT 50 values for 685734 and the negative controls (726415 and 725904) were <8 (with and without GPC). Consistent with previous results [10] , the MARV FRNT 50 values of the MR201 positive control were 325 μg/mL (32.5 µg; with and without GPC).
The EBOV convalescent nonhuman primate (NHP) pooled sera (703547; EBOV FRNT 100 = 16) and the naive NHP pooled sera (703694; EBOV FRNT 100 <8) were selected as the positive and negative controls, respectively, for subsequent testing. All 20 EBOV convalescent ERB sera exhibited EBOV FRNT 100 values <8; however, 4 sera (214838, 546240, 691073, and 721253) exhibited dilution effects at lower serum dilutions and were selected for further testing. The EBOV FRNT 50 values with and without GPC for all 4 of these EBOV convalescent ERB sera, as well as the naive NHP pooled sera negative control (703694), were <8. As previously shown [11] , the EBOV convalescent NHP pooled sera positive control (703547) was able to neutralize EBOV infectivity (FRNT 50 = 16, and FRNT 50 with GPC = 128).
Initial screening of the SOSV convalescent human serum (SOSV FRNT 100 = 800) and 2 naive ERB plasma specimens (726415 and 725904; SOSV FRNT 100 <8) confirmed their selection as the positive and negative controls, respectively. All 3 SOSV convalescent ERB plasma specimens exhibited SOSV FRNT 100 values <8; however, 2 plasma specimens (289953 and 290040) exhibited dilution effects at lower plasma dilutions. Further testing of these 2 samples revealed they were only able to neutralize SOSV in the presence of GPC (289953: FRNT 50 <8, and FRNT 50 with GPC = 16; 290040: FRNT 50 <8, and FRNT 50 with GPC = 32). The SOSV convalescent human serum positive control (FRNT 50 = 8192, and FRNT 50 with GPC = 32 768) and the 2 naive ERB plasma negative controls (726415 and 725904; FRNT 50 <8 with and without GPC) performed as expected.
DISCUSSION
In this study, we systematically tested the ability of >50 MARV, EBOV, and SOSV convalescent ERB sera to neutralize live homologous virus. Our results demonstrate that the effective control and clearance of these viruses by ERBs does not appear to be mediated by virus-specific neutralizing antibodies. However, testing of additional SOSV convalescent sera from ERBs, including samples collected later in convalescence and after secondary viral exposure, is needed to firmly rule out antibody-mediated virus neutralization as a mechanism for SOSV control. Nevertheless, the results of this study suggest that ERBs may rely on other antibody-mediated functions (ie, phagocytosis or antibody-dependent cellular cytotoxicity) and/or the innate immune response to modulate infection with these viruses that are otherwise pathogenic to humans. A recent analysis of the ERB genome uncovered expanded and diversified natural killer cell receptor families, major histocompatibility complex class I genes, and type I interferons, and a theoretical functional analysis of these genes suggested that they might allow bats to tolerate viral infection in the absence of clinically apparent disease [12] . 
